Testicular cancer medical therapy: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
No edit summary
Farima Kahe (talk | contribs)
Bureaucrats, bureaucrats, nocaptcha, Administrators
4,723 edits
No edit summary
Line 11: Line 11:
Seminoma:
Seminoma:


Seminoma is sensitive to radiotherapy and chemotherapy.
Seminoma is sensitive to [[radiotherapy]] and [[chemotherapy]].


Stage IA and IB<ref name="OliverDieckmann2005">{{cite journal|last1=Oliver|first1=T.|last2=Dieckmann|first2=K.-P.|last3=Steiner|first3=H.|last4=Skoneczna|first4=I.|title=Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma|journal=Journal of Clinical Oncology|volume=23|issue=16_suppl|year=2005|pages=4572–4572|issn=0732-183X|doi=10.1200/jco.2005.23.16_suppl.4572}}</ref>
Stage IA and IB<ref name="OliverDieckmann2005">{{cite journal|last1=Oliver|first1=T.|last2=Dieckmann|first2=K.-P.|last3=Steiner|first3=H.|last4=Skoneczna|first4=I.|title=Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma|journal=Journal of Clinical Oncology|volume=23|issue=16_suppl|year=2005|pages=4572–4572|issn=0732-183X|doi=10.1200/jco.2005.23.16_suppl.4572}}</ref>
*Surveillance for pT1-T3 tumors or
*Surveillance for pT1-T3 tumors or
*Single agent carboplatin for 1 or 2 cycles followed with chest X-ray and CT scan of the abdomen and pelvis <ref name="pmid27618772">{{cite journal |vauthors=Chovanec M, Hanna N, Cary KC, Einhorn L, Albany C |title=Management of stage I testicular germ cell tumours |journal=Nat Rev Urol |volume=13 |issue=11 |pages=663–673 |date=November 2016 |pmid=27618772 |doi=10.1038/nrurol.2016.164 |url=}}</ref><ref>"NCCN Clinical Practice Guidelines in Oncology: Testicular cancer. National comprehensive cancer network, 2019; https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf."</ref>
*Single agent carboplatin for 1 or 2 cycles followed with [[chest x-ray]] and [[CT scan]] of the abdomen and pelvis <ref name="pmid27618772">{{cite journal |vauthors=Chovanec M, Hanna N, Cary KC, Einhorn L, Albany C |title=Management of stage I testicular germ cell tumours |journal=Nat Rev Urol |volume=13 |issue=11 |pages=663–673 |date=November 2016 |pmid=27618772 |doi=10.1038/nrurol.2016.164 |url=}}</ref><ref>"NCCN Clinical Practice Guidelines in Oncology: Testicular cancer. National comprehensive cancer network, 2019; https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf."</ref>
* Radiation therapy
* [[Radiation therapy]]
Stage IS  
Stage IS  
*Recheck the serum marker and the chest X-ray and Ct scan of abdomen and pelvis
*Recheck the serum marker and the chest X-ray and Ct scan of abdomen and pelvis
Stage IIA
Stage IIA
*[[Bleomycin]], [[etoposide]], and [[cisplatin]] for 3 cycles or [[etoposide]], and [[cisplatin]] for 4 cycles.
*[[Bleomycin]], [[etoposide]], and [[cisplatin]] for 3 cycles or [[etoposide]], and [[cisplatin]] for 4 cycles.
*Low dose of radiation therapy is preferred over chemotherapy.
*Low dose of radiation therapy is preferred over [[chemotherapy]].


Stage IIB or IIC
Stage IIB or IIC
*[[Bleomycin]], [[etoposide]], and [[cisplatin]] for 3 cycles or [[etoposide]], and [[cisplatin]] for 4 cycles.
*[[Bleomycin]], [[etoposide]], and [[cisplatin]] for 3 cycles or [[etoposide]], and [[cisplatin]] for 4 cycles.
*Combined chemotherapy is recommended over radiation therapy.
*Combined [[chemotherapy]] is recommended over [[radiation therapy]].
===Radiation therapy===
===Radiation therapy===
* [[Radiation therapy]] works best for seminomas. Non-seminomas do not respond well to radiation therapy.
* [[Radiation therapy]] works best for seminomas. Non-seminomas do not respond well to radiation therapy.
* [[External beam radiotherapy|External beam radiation]] may be used for stage I and most stage II seminomas after [[orchiectomy]].<ref name="pmid22436787">{{cite journal |vauthors=Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ |title=Radiotherapy treatment planning for testicular seminoma |journal=Int. J. Radiat. Oncol. Biol. Phys. |volume=83 |issue=4 |pages=e445–52 |date=July 2012 |pmid=22436787 |doi=10.1016/j.ijrobp.2012.01.044 |url=}}</ref>
* [[External beam radiotherapy|External beam radiation]] may be used for stage I and most stage II seminomas after [[orchiectomy]].<ref name="pmid22436787">{{cite journal |vauthors=Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ |title=Radiotherapy treatment planning for testicular seminoma |journal=Int. J. Radiat. Oncol. Biol. Phys. |volume=83 |issue=4 |pages=e445–52 |date=July 2012 |pmid=22436787 |doi=10.1016/j.ijrobp.2012.01.044 |url=}}</ref>
* Radiation therapy after ochiectomy including the para-aortic and ipsilateral iliac lymph nodes for stage IIA seminoma<ref>"NCCN Clinical Practice Guidelines in Oncology: Testicular cancer. National comprehensive cancer network, 2019; https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf."</ref>
* [[Radiation therapy]] after [[orchiectomy]] including the para-aortic and ipsilateral iliac lymph nodes for stage IIA seminoma.<ref>"NCCN Clinical Practice Guidelines in Oncology: Testicular cancer. National comprehensive cancer network, 2019; https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf."</ref>
* Radiation therapy in selected non bulky (3 cm or < 3 cm) including the para-aortic and ipsilateral iliac lymph nodes for stage IIB seminoma.<ref>"NCCN Clinical Practice Guidelines in Oncology: Testicular cancer. National comprehensive cancer network, 2019; https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf."</ref><ref name="pmid12637477">{{cite journal |vauthors=Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Köhrmann KU, Bamberg M |title=Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial |journal=J. Clin. Oncol. |volume=21 |issue=6 |pages=1101–6 |date=March 2003 |pmid=12637477 |doi=10.1200/JCO.2003.06.065 |url=}}</ref>
* Radiation therapy in selected non bulky (3 cm or < 3 cm) including the para-aortic and ipsilateral iliac lymph nodes for stage IIB seminoma.<ref>"NCCN Clinical Practice Guidelines in Oncology: Testicular cancer. National comprehensive cancer network, 2019; https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf."</ref><ref name="pmid12637477">{{cite journal |vauthors=Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Köhrmann KU, Bamberg M |title=Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial |journal=J. Clin. Oncol. |volume=21 |issue=6 |pages=1101–6 |date=March 2003 |pmid=12637477 |doi=10.1200/JCO.2003.06.065 |url=}}</ref>
* Radiation treatments are usually given once a day, 5 days a week, for 2–4 weeks.
* Radiation treatments are usually given once a day, 5 days a week, for 2–4 weeks.
Line 40: Line 40:
:* [[Etoposide]] and [[cisplatin]] are given for 4 cycles for metastasis to brain, stage IIA, IIB, IIC and good risk stage III seminoma as well as good risk stage IIA, IIB, and stage IIC, IIIA Nonseminoma<ref name="pmid2446132">{{cite journal |vauthors=Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT |title=Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer |journal=N. Engl. J. Med. |volume=317 |issue=23 |pages=1433–8 |date=December 1987 |pmid=2446132 |doi=10.1056/NEJM198712033172303 |url=}}</ref>
:* [[Etoposide]] and [[cisplatin]] are given for 4 cycles for metastasis to brain, stage IIA, IIB, IIC and good risk stage III seminoma as well as good risk stage IIA, IIB, and stage IIC, IIIA Nonseminoma<ref name="pmid2446132">{{cite journal |vauthors=Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT |title=Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer |journal=N. Engl. J. Med. |volume=317 |issue=23 |pages=1433–8 |date=December 1987 |pmid=2446132 |doi=10.1056/NEJM198712033172303 |url=}}</ref>
::* It is used when bleomycin affects the lungs or there is a high risk that it will cause lung damage.
::* It is used when bleomycin affects the lungs or there is a high risk that it will cause lung damage.
:* [[Bleomycin]], [[etoposide]], and [[cisplatin]] or Etoposide, [[mesna]], [[ifosfamide]], and cisplatin  are given for 4 cycles for intermediate risk stage III seminoma and intermediate and poor risk stage IIIC Nonseminoma.
:* [[Bleomycin]], [[etoposide]], and [[cisplatin]] or [[etoposide]], [[mesna]], [[ifosfamide]], and [[cisplatin]] are given for 4 cycles for intermediate risk stage III seminoma and intermediate and poor risk stage IIIC Nonseminoma.
::* [[Bleomycin]], [[etoposide]], and [[cisplatin]] for 1 cycle for stage I nonseminoma with and without risk factors<ref name="pmid19875756">{{cite journal |vauthors=Kollmannsberger C, Moore C, Chi KN, Murray N, Daneshmand S, Gleave M, Hayes-Lattin B, Nichols CR |title=Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy |journal=Ann. Oncol. |volume=21 |issue=6 |pages=1296–301 |date=June 2010 |pmid=19875756 |doi=10.1093/annonc/mdp473 |url=}}</ref>
::* [[Bleomycin]], [[etoposide]], and [[cisplatin]] for 1 cycle for stage I nonseminoma with and without risk factors<ref name="pmid19875756">{{cite journal |vauthors=Kollmannsberger C, Moore C, Chi KN, Murray N, Daneshmand S, Gleave M, Hayes-Lattin B, Nichols CR |title=Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy |journal=Ann. Oncol. |volume=21 |issue=6 |pages=1296–301 |date=June 2010 |pmid=19875756 |doi=10.1093/annonc/mdp473 |url=}}</ref>


* If testicular cancer does not respond to the above drugs or if it recurs, the following chemotherapy combinations may be used. These are sometimes called salvage, or second-line, chemotherapy.
* If testicular cancer does not respond to the above drugs or if it recurs, the following chemotherapy combinations may be used. These are sometimes called salvage, or second-line, [[chemotherapy]].
:* [[Paclitaxel]], ifosfamide and cisplatin
:* [[Paclitaxel]], [[ifosfamide]] and [[cisplatin]]
::* It is given IV every 3 weeks for 3 months, or 4 cycles.
::* It is given IV every 3 weeks for 3 months, or 4 cycles.
:* Etoposide, ifosfamide and cisplatin.
:* [[Etoposide]], [[ifosfamide]] and [[cisplatin]]
::* It is given IV every 3 weeks for 3 months, or 4 cycles.
::* It is given IV every 3 weeks for 3 months, or 4 cycles.
:* Etoposide or [[vinblastine]], ifosfamide and cisplatin
:* [[Etoposide]] or [[vinblastine]], [[ifosfamide]] and [[cisplatin]]
::* It is given IV every 3 weeks for 3 months, or 4 cycles.
::* It is given IV every 3 weeks for 3 months, or 4 cycles.


'''High-dose chemotherapy'''
'''High-dose chemotherapy'''
* High-dose chemotherapy with [[carboplatin]] and [[etoposide]] may be used if testicular cancer recurs after it is treated with standard-dose chemotherapy.
* High-dose [[chemotherapy]] with [[carboplatin]] and [[etoposide]] may be used if testicular cancer recurs after it is treated with standard-dose [[chemotherapy]].


'''Palliative chemotherapy'''
'''Palliative chemotherapy'''
* Palliative therapy is given to relieve symptoms, rather than to treat the cancer itself. [[Gemcitabine]] may be given with [[oxaliplatin]], [[paclitaxel]] or both as palliative treatment for seminomas or non-seminoma.
* [[Palliative therapy]] is given to relieve symptoms, rather than to treat the cancer itself. [[Gemcitabine]] may be given with [[oxaliplatin]], [[paclitaxel]] or both as palliative treatment for seminomas or non-seminoma.
===Sex cord stromal testicular tumors===
===Sex cord stromal testicular tumors===
*Most sex cord stromal testicular tumors may not respond to chemotherapy and radiation.<ref name="pmid16097561">{{cite journal |vauthors=Conkey DS, Howard GC, Grigor KM, McLaren DB, Kerr GR |title=Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature |journal=Clin Oncol (R Coll Radiol) |volume=17 |issue=5 |pages=322–7 |date=August 2005 |pmid=16097561 |doi= |url=}}</ref><ref name="pmid10971169">{{cite journal |vauthors=Farkas LM, Székely JG, Pusztai C, Baki M |title=High frequency of metastatic Leydig cell testicular tumours |journal=Oncology |volume=59 |issue=2 |pages=118–21 |date=August 2000 |pmid=10971169 |doi=10.1159/000012147 |url=}}</ref>
*Most sex cord stromal testicular tumors may not respond to [[chemotherapy]] and [[radiation]].<ref name="pmid16097561">{{cite journal |vauthors=Conkey DS, Howard GC, Grigor KM, McLaren DB, Kerr GR |title=Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature |journal=Clin Oncol (R Coll Radiol) |volume=17 |issue=5 |pages=322–7 |date=August 2005 |pmid=16097561 |doi= |url=}}</ref><ref name="pmid10971169">{{cite journal |vauthors=Farkas LM, Székely JG, Pusztai C, Baki M |title=High frequency of metastatic Leydig cell testicular tumours |journal=Oncology |volume=59 |issue=2 |pages=118–21 |date=August 2000 |pmid=10971169 |doi=10.1159/000012147 |url=}}</ref>
*Adjuvants are not helpful nor effective
*[[Adjuvants]] are not helpful nor effective.
 
|}


==References==
==References==

Revision as of 13:46, 22 May 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gertrude Djouka, M.D.[2], Shanshan Cen, M.D. [3]

Testicular cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Testicular cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Testicular cancer medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Testicular cancer medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Testicular cancer medical therapy

CDC on Testicular cancer medical therapy

Testicular cancer medical therapy in the news

Blogs on Testicular cancer medical therapy

Directions to Hospitals Treating Testicular cancer

Risk calculators and risk factors for Testicular cancer medical therapy

Overview

The predominant therapy for testicular cancer is surgical resection. Adjunctive chemotherapy and radiation therapy may be required.

Medical Therapy

Germ cell tumors

Seminoma:

Seminoma is sensitive to radiotherapy and chemotherapy.

Stage IA and IB[1]

Stage IS

  • Recheck the serum marker and the chest X-ray and Ct scan of abdomen and pelvis

Stage IIA

Stage IIB or IIC

Radiation therapy

  • Radiation therapy works best for seminomas. Non-seminomas do not respond well to radiation therapy.
  • External beam radiation may be used for stage I and most stage II seminomas after orchiectomy.[4]
  • Radiation therapy after orchiectomy including the para-aortic and ipsilateral iliac lymph nodes for stage IIA seminoma.[5]
  • Radiation therapy in selected non bulky (3 cm or < 3 cm) including the para-aortic and ipsilateral iliac lymph nodes for stage IIB seminoma.[6][7]
  • Radiation treatments are usually given once a day, 5 days a week, for 2–4 weeks.

Chemotherapy

Standard-dose chemotherapy[8][9]

  • The most common chemotherapy combinations used to treat testicular cancer are:
  • It is usually given IV every 3 weeks for 3 months for 3 cycles for metastasis to brain, stage IIA, IIB, IIC, and good risk stage III seminoma as well as good risk stage IIA, IIB, and stage IIC, IIIA Nonseminoma.
  • Etoposide and cisplatin are given for 4 cycles for metastasis to brain, stage IIA, IIB, IIC and good risk stage III seminoma as well as good risk stage IIA, IIB, and stage IIC, IIIA Nonseminoma[10]
  • It is used when bleomycin affects the lungs or there is a high risk that it will cause lung damage.
  • If testicular cancer does not respond to the above drugs or if it recurs, the following chemotherapy combinations may be used. These are sometimes called salvage, or second-line, chemotherapy.
  • It is given IV every 3 weeks for 3 months, or 4 cycles.
  • It is given IV every 3 weeks for 3 months, or 4 cycles.
  • It is given IV every 3 weeks for 3 months, or 4 cycles.

High-dose chemotherapy

Palliative chemotherapy

Sex cord stromal testicular tumors

References

  1. ↑ Oliver, T.; Dieckmann, K.-P.; Steiner, H.; Skoneczna, I. (2005). "Pooled analysis of phase 2 reports of 2 v 1 course of carboplatin as adjuvant for stage 1 seminoma". Journal of Clinical Oncology. 23 (16_suppl): 4572–4572. doi:10.1200/jco.2005.23.16_suppl.4572. ISSN 0732-183X.
  2. ↑ Chovanec M, Hanna N, Cary KC, Einhorn L, Albany C (November 2016). "Management of stage I testicular germ cell tumours". Nat Rev Urol. 13 (11): 663–673. doi:10.1038/nrurol.2016.164. PMID 27618772.
  3. ↑ "NCCN Clinical Practice Guidelines in Oncology: Testicular cancer. National comprehensive cancer network, 2019; https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf."
  4. ↑ Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ (July 2012). "Radiotherapy treatment planning for testicular seminoma". Int. J. Radiat. Oncol. Biol. Phys. 83 (4): e445–52. doi:10.1016/j.ijrobp.2012.01.044. PMID 22436787.
  5. ↑ "NCCN Clinical Practice Guidelines in Oncology: Testicular cancer. National comprehensive cancer network, 2019; https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf."
  6. ↑ "NCCN Clinical Practice Guidelines in Oncology: Testicular cancer. National comprehensive cancer network, 2019; https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf."
  7. ↑ Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Köhrmann KU, Bamberg M (March 2003). "Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial". J. Clin. Oncol. 21 (6): 1101–6. doi:10.1200/JCO.2003.06.065. PMID 12637477.
  8. ↑ "International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group". J. Clin. Oncol. 15 (2): 594–603. February 1997. doi:10.1200/JCO.1997.15.2.594. PMID 9053482.
  9. ↑ Garcia-del-Muro X, Maroto P, Gumà J, Sastre J, López Brea M, Arranz JA, Lainez N, Soto de Prado D, Aparicio J, Piulats JM, Pérez X, Germá-Lluch JR (November 2008). "Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study". J. Clin. Oncol. 26 (33): 5416–21. doi:10.1200/JCO.2007.15.9103. PMID 18936476.
  10. ↑ Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, Paulson DF, Brunner KW, Jacobs EM, Spaulding JT (December 1987). "Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer". N. Engl. J. Med. 317 (23): 1433–8. doi:10.1056/NEJM198712033172303. PMID 2446132.
  11. ↑ Kollmannsberger C, Moore C, Chi KN, Murray N, Daneshmand S, Gleave M, Hayes-Lattin B, Nichols CR (June 2010). "Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy". Ann. Oncol. 21 (6): 1296–301. doi:10.1093/annonc/mdp473. PMID 19875756.
  12. ↑ Conkey DS, Howard GC, Grigor KM, McLaren DB, Kerr GR (August 2005). "Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature". Clin Oncol (R Coll Radiol). 17 (5): 322–7. PMID 16097561.
  13. ↑ Farkas LM, Székely JG, Pusztai C, Baki M (August 2000). "High frequency of metastatic Leydig cell testicular tumours". Oncology. 59 (2): 118–21. doi:10.1159/000012147. PMID 10971169.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Testicular_cancer_medical_therapy&oldid=1569349"